Medical - Devices
Compare Stocks
5 / 10Stock Comparison
TCMD vs LNTH vs MDT vs RMD vs BSX
Revenue, margins, valuation, and 5-year total return — side by side.
Drug Manufacturers - Specialty & Generic
Medical - Devices
Medical - Instruments & Supplies
Medical - Devices
TCMD vs LNTH vs MDT vs RMD vs BSX — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Devices | Drug Manufacturers - Specialty & Generic | Medical - Devices | Medical - Instruments & Supplies | Medical - Devices |
| Market Cap | $587M | $5.92B | $99.94B | $30.15B | $84.08B |
| Revenue (TTM) | $344M | $1.55B | $35.48B | $5.54B | $20.07B |
| Net Income (TTM) | $20M | $279M | $4.61B | $1.52B | $2.89B |
| Gross Margin | 75.7% | 60.5% | 61.9% | 61.7% | 69.0% |
| Operating Margin | 9.4% | 18.8% | 17.9% | 34.3% | 19.8% |
| Forward P/E | 22.8x | 17.5x | 14.1x | 18.8x | 16.7x |
| Total Debt | $16M | $738K | $28.52B | $852M | $12.42B |
| Cash & Equiv. | $83M | $359M | $2.22B | $1.21B | $2.04B |
TCMD vs LNTH vs MDT vs RMD vs BSX — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Tactile Systems Tec… (TCMD) | 100 | 53.7 | -46.3% |
| Lantheus Holdings, … (LNTH) | 100 | 662.8 | +562.8% |
| Medtronic plc (MDT) | 100 | 79.1 | -20.9% |
| ResMed Inc. (RMD) | 100 | 128.7 | +28.7% |
| Boston Scientific C… (BSX) | 100 | 148.9 | +48.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: TCMD vs LNTH vs MDT vs RMD vs BSX
Each card shows where this stock fits in a portfolio — not just who wins on paper.
TCMD ranks third and is worth considering specifically for momentum.
- +169.8% vs BSX's -46.0%
LNTH is the clearest fit if your priority is long-term compounding and sleep-well-at-night.
- 41.9% 10Y total return vs RMD's 293.8%
- Lower volatility, beta 0.47, Low D/E 0.1%, current ratio 2.70x
MDT carries the broadest edge in this set and is the clearest fit for income & stability and defensive.
- Dividend streak 36 yrs, beta 0.47, yield 3.6%
- Beta 0.47, yield 3.6%, current ratio 1.85x
- Lower P/E (14.1x vs 16.7x)
- 3.6% yield, 36-year raise streak, vs RMD's 1.0%, (3 stocks pay no dividend)
RMD is the clearest fit if your priority is valuation efficiency.
- PEG 1.08 vs MDT's 36.00
- 27.4% margin vs TCMD's 5.9%
BSX is the #2 pick in this set and the best alternative if growth exposure is your priority.
- Rev growth 19.9%, EPS growth 55.2%, 3Y rev CAGR 16.5%
- 19.9% revenue growth vs LNTH's 0.5%
- Beta 0.34 vs TCMD's 0.99
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 19.9% revenue growth vs LNTH's 0.5% | |
| Value | Lower P/E (14.1x vs 16.7x) | |
| Quality / Margins | 27.4% margin vs TCMD's 5.9% | |
| Stability / Safety | Beta 0.34 vs TCMD's 0.99 | |
| Dividends | 3.6% yield, 36-year raise streak, vs RMD's 1.0%, (3 stocks pay no dividend) | |
| Momentum (1Y) | +169.8% vs BSX's -46.0% | |
| Efficiency (ROA) | 175.8% ROA vs BSX's 6.9%, ROIC 6.0% vs 8.8% |
TCMD vs LNTH vs MDT vs RMD vs BSX — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
TCMD vs LNTH vs MDT vs RMD vs BSX — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
MDT leads in 2 of 6 categories
RMD leads 1 • LNTH leads 1 • TCMD leads 0 • BSX leads 0 • 2 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
RMD leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
MDT is the larger business by revenue, generating $35.5B annually — 103.3x TCMD's $344M. RMD is the more profitable business, keeping 27.4% of every revenue dollar as net income compared to TCMD's 5.9%. On growth, TCMD holds the edge at +22.8% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $344M | $1.5B | $35.5B | $5.5B | $20.1B |
| EBITDAEarnings before interest/tax | $39M | $347M | $9.4B | $2.1B | $4.7B |
| Net IncomeAfter-tax profit | $20M | $279M | $4.6B | $1.5B | $2.9B |
| Free Cash FlowCash after capex | $39M | $372M | $5.4B | $1.8B | $3.6B |
| Gross MarginGross profit ÷ Revenue | +75.7% | +60.5% | +61.9% | +61.7% | +69.0% |
| Operating MarginEBIT ÷ Revenue | +9.4% | +18.8% | +17.9% | +34.3% | +19.8% |
| Net MarginNet income ÷ Revenue | +5.9% | +18.0% | +13.0% | +27.4% | +14.4% |
| FCF MarginFCF ÷ Revenue | +11.4% | +24.0% | +15.2% | +31.7% | +18.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | +22.8% | +1.2% | +8.8% | +10.8% | +15.9% |
| EPS Growth (YoY)Latest quarter vs prior year | +38.5% | +76.5% | -11.9% | +9.3% | +18.5% |
Valuation Metrics
MDT leads this category, winning 4 of 7 comparable metrics.
Valuation Metrics
At 21.6x trailing earnings, MDT trades at a 32% valuation discount to TCMD's 31.7x P/E. Adjusting for growth (PEG ratio), RMD offers better value at 1.25x vs MDT's 36.00x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $587M | $5.9B | $99.9B | $30.1B | $84.1B |
| Enterprise ValueMkt cap + debt − cash | $519M | $5.6B | $126.2B | $29.8B | $94.5B |
| Trailing P/EPrice ÷ TTM EPS | 31.72x | 26.69x | 21.60x | 21.76x | 29.16x |
| Forward P/EPrice ÷ next-FY EPS est. | 22.82x | 17.52x | 14.13x | 18.78x | 16.75x |
| PEG RatioP/E ÷ EPS growth rate | — | — | 36.00x | 1.25x | — |
| EV / EBITDAEnterprise value multiple | 14.45x | 14.61x | 14.32x | 15.51x | 25.30x |
| Price / SalesMarket cap ÷ Revenue | 1.78x | 3.84x | 2.98x | 5.86x | 4.19x |
| Price / BookPrice ÷ Book value/share | 2.77x | 5.72x | 2.08x | 5.11x | 3.46x |
| Price / FCFMarket cap ÷ FCF | 14.51x | 16.73x | 19.28x | 18.14x | 22.99x |
Profitability & Efficiency
LNTH leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
RMD delivers a 24.4% return on equity — every $100 of shareholder capital generates $24 in annual profit, vs $9 for MDT. LNTH carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to MDT's 0.59x. On the Piotroski fundamental quality scale (0–9), TCMD scores 8/9 vs LNTH's 5/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +9.7% | +24.3% | +9.4% | +24.4% | +12.4% |
| ROA (TTM)Return on assets | +7.5% | +12.4% | +175.8% | +18.0% | +6.9% |
| ROICReturn on invested capital | +13.8% | +30.6% | +6.0% | +22.8% | +8.8% |
| ROCEReturn on capital employed | +11.9% | +17.1% | +7.5% | +25.7% | +11.1% |
| Piotroski ScoreFundamental quality 0–9 | 8 | 5 | 6 | 8 | 7 |
| Debt / EquityFinancial leverage | 0.07x | 0.00x | 0.59x | 0.14x | 0.51x |
| Net DebtTotal debt minus cash | -$67M | -$358M | $26.3B | -$358M | $10.4B |
| Cash & Equiv.Liquid assets | $83M | $359M | $2.2B | $1.2B | $2.0B |
| Total DebtShort + long-term debt | $16M | $738,000 | $28.5B | $852M | $12.4B |
| Interest CoverageEBIT ÷ Interest expense | 76.34x | 11.72x | 9.08x | 66.06x | 11.03x |
Total Returns (Dividends Reinvested)
Evenly matched — TCMD and LNTH each lead in 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in LNTH five years ago would be worth $41,420 today (with dividends reinvested), compared to $4,652 for TCMD. Over the past 12 months, TCMD leads with a +169.8% total return vs BSX's -46.0%. The 3-year compound annual growth rate (CAGR) favors TCMD at 11.5% vs RMD's -2.9% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -5.1% | +35.3% | -18.1% | -15.2% | -40.3% |
| 1-Year ReturnPast 12 months | +169.8% | +13.1% | -2.8% | -14.5% | -46.0% |
| 3-Year ReturnCumulative with dividends | +38.8% | -4.0% | -4.2% | -8.4% | +6.5% |
| 5-Year ReturnCumulative with dividends | -53.5% | +314.2% | -27.7% | +11.0% | +31.2% |
| 10-Year ReturnCumulative with dividends | +134.7% | +4192.5% | +26.5% | +293.8% | +155.5% |
| CAGR (3Y)Annualised 3-year return | +11.5% | -1.4% | -1.4% | -2.9% | +2.1% |
Risk & Volatility
Evenly matched — LNTH and BSX each lead in 1 of 2 comparable metrics.
Risk & Volatility
BSX is the less volatile stock with a 0.34 beta — it tends to amplify market swings less than TCMD's 0.99 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. LNTH currently trades 97.8% from its 52-week high vs BSX's 51.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.99x | 0.47x | 0.47x | 0.66x | 0.34x |
| 52-Week HighHighest price in past year | $37.75 | $93.00 | $106.33 | $293.81 | $109.50 |
| 52-Week LowLowest price in past year | $9.34 | $47.25 | $77.16 | $198.64 | $54.98 |
| % of 52W HighCurrent price vs 52-week peak | +68.9% | +97.8% | +73.3% | +70.4% | +51.7% |
| RSI (14)Momentum oscillator 0–100 | 53.9 | 61.2 | 27.3 | 35.6 | 33.2 |
| Avg Volume (50D)Average daily shares traded | 279K | 886K | 7.8M | 1.1M | 15.5M |
Analyst Outlook
MDT leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: TCMD as "Buy", LNTH as "Buy", MDT as "Buy", RMD as "Buy", BSX as "Buy". Consensus price targets imply 61.4% upside for BSX (target: $91) vs 11.0% for LNTH (target: $101). For income investors, MDT offers the higher dividend yield at 3.57% vs RMD's 1.02%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $38.75 | $101.00 | $109.50 | $281.29 | $91.33 |
| # AnalystsCovering analysts | 11 | 17 | 49 | 35 | 43 |
| Dividend YieldAnnual dividend ÷ price | — | — | +3.6% | +1.0% | — |
| Dividend StreakConsecutive years of raises | 1 | 0 | 36 | 14 | 0 |
| Dividend / ShareAnnual DPS | — | — | $2.78 | $2.11 | — |
| Buyback YieldShare repurchases ÷ mkt cap | +4.5% | +5.1% | +3.2% | +1.0% | 0.0% |
MDT leads in 2 of 6 categories (Valuation Metrics, Analyst Outlook). RMD leads in 1 (Income & Cash Flow). 2 tied.
TCMD vs LNTH vs MDT vs RMD vs BSX: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is TCMD or LNTH or MDT or RMD or BSX a better buy right now?
For growth investors, Boston Scientific Corporation (BSX) is the stronger pick with 19.
9% revenue growth year-over-year, versus 0. 5% for Lantheus Holdings, Inc. (LNTH). Medtronic plc (MDT) offers the better valuation at 21. 6x trailing P/E (14. 1x forward), making it the more compelling value choice. Analysts rate Tactile Systems Technology, Inc. (TCMD) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — TCMD or LNTH or MDT or RMD or BSX?
On trailing P/E, Medtronic plc (MDT) is the cheapest at 21.
6x versus Tactile Systems Technology, Inc. at 31. 7x. On forward P/E, Medtronic plc is actually cheaper at 14. 1x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: ResMed Inc. wins at 1. 08x versus Medtronic plc's 36. 00x — a reasonable growth-adjusted valuation.
03Which is the better long-term investment — TCMD or LNTH or MDT or RMD or BSX?
Over the past 5 years, Lantheus Holdings, Inc.
(LNTH) delivered a total return of +314. 2%, compared to -53. 5% for Tactile Systems Technology, Inc. (TCMD). Over 10 years, the gap is even starker: LNTH returned +41. 9% versus MDT's +26. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — TCMD or LNTH or MDT or RMD or BSX?
By beta (market sensitivity over 5 years), Boston Scientific Corporation (BSX) is the lower-risk stock at 0.
34β versus Tactile Systems Technology, Inc. 's 0. 99β — meaning TCMD is approximately 189% more volatile than BSX relative to the S&P 500. On balance sheet safety, Lantheus Holdings, Inc. (LNTH) carries a lower debt/equity ratio of 0% versus 59% for Medtronic plc — giving it more financial flexibility in a downturn.
05Which is growing faster — TCMD or LNTH or MDT or RMD or BSX?
By revenue growth (latest reported year), Boston Scientific Corporation (BSX) is pulling ahead at 19.
9% versus 0. 5% for Lantheus Holdings, Inc. (LNTH). On earnings-per-share growth, the picture is similar: Boston Scientific Corporation grew EPS 55. 2% year-over-year, compared to -21. 8% for Lantheus Holdings, Inc.. Over a 3-year CAGR, LNTH leads at 18. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — TCMD or LNTH or MDT or RMD or BSX?
ResMed Inc.
(RMD) is the more profitable company, earning 27. 2% net margin versus 5. 8% for Tactile Systems Technology, Inc. — meaning it keeps 27. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RMD leads at 32. 7% versus 8. 9% for TCMD. At the gross margin level — before operating expenses — TCMD leads at 75. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is TCMD or LNTH or MDT or RMD or BSX more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, ResMed Inc. (RMD) is the more undervalued stock at a PEG of 1. 08x versus Medtronic plc's 36. 00x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Medtronic plc (MDT) trades at 14. 1x forward P/E versus 22. 8x for Tactile Systems Technology, Inc. — 8. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for BSX: 61. 4% to $91. 33.
08Which pays a better dividend — TCMD or LNTH or MDT or RMD or BSX?
In this comparison, MDT (3.
6% yield), RMD (1. 0% yield) pay a dividend. TCMD, LNTH, BSX do not pay a meaningful dividend and should not be held primarily for income.
09Is TCMD or LNTH or MDT or RMD or BSX better for a retirement portfolio?
For long-horizon retirement investors, ResMed Inc.
(RMD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 66), 1. 0% yield, +293. 8% 10Y return). Both have compounded well over 10 years (RMD: +293. 8%, TCMD: +134. 7%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between TCMD and LNTH and MDT and RMD and BSX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: TCMD is a small-cap quality compounder stock; LNTH is a small-cap quality compounder stock; MDT is a mid-cap income-oriented stock; RMD is a mid-cap quality compounder stock; BSX is a mid-cap high-growth stock. MDT, RMD pay a dividend while TCMD, LNTH, BSX do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.